Psychedelic-assisted therapy is an emerging field of mental health treatment that involves the use of psychedelic substances in a therapeutic setting to facilitate emotional, psychological, and spiritual healing. This approach combines traditional psychotherapy with the controlled administration of psychedelics such as psilocybin (found in magic mushrooms), LSD, MDMA (Street name – ecstasy), and Ayahuasca. The resurgence of interest in psychedelic research and therapy is largely due to recent clinical trials showing promising results for conditions that are often resistant to conventional treatments, such as depression, post-traumatic stress disorder (PTSD), addiction, and anxiety associated with life-threatening illnesses. It is illegal in the UK to use psychedelic substance so we run regular retreats in Europe where we are legally allowed to offer this therapeutic modality. Please get in touch if you want to know more about this type of interventions.
How It Works
Psychedelic-assisted therapy typically involves several stages:
- Preparation: Before administering any psychedelic substance, therapists work with clients to prepare them for the experience. This preparation includes discussing the client’s intentions, what they might expect, and how to navigate the psychedelic experience effectively.
- Administration: The psychedelic substance is administered in a controlled, safe environment, under the supervision of trained therapists. The dosage and substance depend on the specific therapeutic goals and the individual’s condition.
- The Psychedelic Experience: During the experience, individuals often encounter deeply emotional, insightful, or spiritual states. Therapists are present to provide support, ensuring safety and helping the individual navigate the experience.
- Integration: After the psychedelic experience, therapists assist individuals in integrating their experiences into their daily lives. This stage is crucial for translating insights gained during the psychedelic state into lasting changes in behaviour, thought patterns, and emotional processing.
Research and Legal Status
Recent studies have shown significant therapeutic potential for psychedelics. For example, psilocybin has been granted “breakthrough therapy” designation by the FDA for treatment-resistant depression and major depressive disorder, accelerating the development and review process. MDMA is also in advanced clinical trials for the treatment of PTSD, showing promising results in reducing symptoms.
Despite these advances, the legal status of psychedelic substances remains a barrier to widespread adoption. In the United States, most psychedelics are classified as Schedule I substances under the Controlled Substances Act, indicating a high potential for abuse and no accepted medical use. However, this classification is increasingly challenged by scientific findings. Some jurisdictions have begun to change their stance on psychedelics, decriminalizing or legalizing their use for therapeutic purposes under strict regulations.
Considerations & Criticisms
Psychedelic-assisted therapy is not without its critics and concerns. Sceptics’ point to the need for more extensive research to understand the long-term effects, potential risks, and the mechanisms by which these substances exert their therapeutic effects. There are also concerns about the potential for abuse and the necessity of ensuring that therapy is conducted by trained and licensed professionals in a controlled environment.
For individuals considering psychedelic-assisted therapy, it’s important to approach this option with caution, thorough research, and professional guidance. As the field evolves and more research becomes available, psychedelic-assisted therapy may offer a valuable alternative or complement to traditional mental health treatments, potentially transforming the landscape of psychiatric care.
